A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome | Journal of Neurodevelopmental Disorders | Full Text
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo- controlled, phase 3 trial - The Lancet Neurology
Marinus Pharmaceuticals Inc 2019 Current Report 8-K
Ganaxolone - Emerging Insight and Market Forecast - 2030
Rare Seizure Disorder Gets Its First Drug Approval | MedPage Today
Clinical trial in which Ganaxolone is used to treat epilepsy in... | Download Table
Ganaxolone
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo- controlled, phase 3 trial - The Lancet Neurology
Ganaxolone Fragile X Clinical Trial Showed Disappointing Results • Fragile X Research - FRAXA Research Foundation
Ganaxolone | CAS:38398-32-2 | Potent, positive allosteric modulator of GABAA receptors | High Purity | Manufacturer BioCrick
Ganaxolone | C22H36O2 - PubChem
Trial design. GNX-GNX group: randomized to ganaxolone for the first... | Download Scientific Diagram
Randomized, double‐blind, placebo‐controlled phase 2 study of ganaxolone as add‐on therapy in adults with uncontrolled partial‐onset seizures - Sperling - 2017 - Epilepsia - Wiley Online Library
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials | Business Wire
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show
Marinus' epilepsy drug receives US FDA rare pediatric disease tag | S&P Global Market Intelligence
Clinical trials to date in fragile X syndrome by drug and study type | Download Table
Dose-response (top) and time-course (bottom) data for ganaxolone,... | Download Scientific Diagram
Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment‐resistant status epilepticus - Zolkowska - 2018 - Epilepsia - Wiley Online Library